Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAS blockade on UFLC in type 2 diabetes
NCT02046395Phase 4Completed
- Sponsor
- Tulane University
- Start
- Jan 2012
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 4, open-label trial in diabetic nephropathy (DN), sponsored by Tulane University. Primary endpoint: Urine Microalbumin Creatinine Ratio at 60 days. Started Jan 2012; status: completed.
02
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02046395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046395.